Anti-CMV Dendritic Cell Vaccine: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

31 March 2024

  • curprev 13:3113:31, 31 March 2024‎ Lazy talk contribs‎ 4,494 bytes +45‎ No edit summary
  • curprev 13:1913:19, 31 March 2024‎ Lazy talk contribs‎ 4,449 bytes +4,449‎ Created page with "{{TreatmentInfo |drug_name=Anti-CMV Dendritic Cell Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II |common_side_effects=Not detailed; dendritic cell vaccines are generally well-tolerated with mild side effects. |OS_without=Historical controls indicate median overall survival around 15-17 months for newly diagnosed GBM. |OS_with=Varied; one study showed medi..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Anti-CMV_Dendritic_Cell_Vaccine"